PubMed 检索式 1（严格窗口 2026/08/17–2026/08/19[pdat]）：("traditional Chinese medicine"[TIAB] OR "Chinese herbal medicine"[TIAB] OR "Chinese medicine"[TIAB] OR acupuncture[TIAB] OR "herbal medicine"[TIAB]) → 命中 10 篇；逐篇读取题录与摘要，剔除前几期已收录条目与主题相关度低者后，3 篇纳入本期（PMID 42608732、42610193、42611346）。
Europe PMC 交叉检索：TITLE_ABS:(TCM 词表) AND FIRST_PDATE:[2026-08-17 TO 2026-08-19] → 1 条（即 PMID 42607276，JCO Oncology Practice 针灸癌症症状控制短评，无摘要、属短评，未纳入；新文献索引延迟符合预期）。
Comparative Efficacy of Body Acupuncture, Electroacupuncture, and Auricular Acupuncture in Stroke Rehabilitation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
作者
Xueqi Qian, Jun Rong, Cunxin Wang, Heng Mou
期刊
American Journal of Physical Medicine & Rehabilitation（美国物理医学与康复杂志）
使用方法：主要结局为运动功能（Fugl-Meyer 量表，FMA）；次要结局包括日常生活活动能力、神经功能与安全性；进行两两比较与贝叶斯网状 Meta 分析，报告 SUCRA 概率排序。
主要结果：与对照相比，针刺显著改善运动功能（SMD=6.48；95% CI 4.72–8.24；P<0.001）。电针获益最大（SMD=7.92；95% CI 5.60–10.24），其次为体针（SMD=5.41；95% CI 3.25–7.57）与耳针（SMD=3.28；95% CI 1.12–5.44）；日常生活活动能力与神经功能缺损亦显著改善。网状 Meta 分析显示，电针成为最有效疗法的概率最高（SUCRA=96.4%）。
英文原摘要（English Abstract，源自 PubMed）：To compare the efficacy of body acupuncture, electroacupuncture, and auricular acupuncture on motor, functional, and neurological recovery after stroke. Systematic review and meta-analysis of randomized controlled trials. Eligible studies enrolled adult stroke survivors receiving one of three acupuncture modalities versus control treatments. Primary outcome was motor function (Fugl-Meyer Assessment). Secondary outcomes included activities of daily living, neurological function, and safety. Pairwise and Bayesian network meta-analyses were conducted. A total of 21 trials were included. Acupuncture significantly improved motor function compared with controls (SMD=6.48; 95% CI=4.72-8.24; P<0.001). Electroacupuncture showed the greatest benefit (SMD=7.92; 95% CI=5.60-10.24), followed by body acupuncture (SMD=5.41; 95% CI=3.25-7.57) and auricular acupuncture (SMD=3.28; 95% CI=1.12-5.44). Significant improvements were also observed in activities of daily living and neurological impairment. Network meta-analysis indicated that electroacupuncture had the highest probability of being among the most effective modalities (SUCRA=96.4%). Electroacupuncture demonstrated the most favorable overall therapeutic profile among the three acupuncture modalities, followed by body acupuncture and auricular acupuncture. These findings support modality-specific acupuncture selection for stroke rehabilitation while highlighting the need for additional head-to-head randomized trials.
中文摘要翻译：目的：比较体针、电针与耳针对卒中后运动、功能与神经功能恢复的疗效。方法：对随机对照试验（RCT）进行系统评价与Meta 分析。纳入接受三种针刺疗法之一与对照治疗比较的成年卒中幸存者。主要结局为运动功能（Fugl-Meyer 量表）；次要结局包括日常生活活动能力、神经功能与安全性。进行两两比较与贝叶斯网状 Meta 分析。结果：共纳入 21 项试验。与对照相比，针刺显著改善运动功能（SMD=6.48；95% CI 4.72–8.24；P<0.001）。电针获益最大（SMD=7.92；95% CI 5.60–10.24），其次为体针（SMD=5.41；95% CI 3.25–7.57）与耳针（SMD=3.28；95% CI 1.12–5.44）。日常生活活动能力与神经功能缺损亦观察到显著改善。网状 Meta 分析显示，电针成为最有效疗法的概率最高（SUCRA=96.4%）。结论：在三种针刺疗法中，电针的总体疗效特征最优，其次为体针与耳针。这些发现支持在卒中康复中按针刺方式个体化选择方案，同时提示需要更多头对头随机对照试验加以验证。
第二部分 · 中医药理论与临床整合（综述）
2中医药治疗类风湿关节炎：临床与分子证据的综合综述
中文题目
中医药治疗类风湿关节炎的治疗特性与作用机制：临床与分子证据的综合综述
英文标题
Therapeutic Properties and Underlying Mechanisms of Traditional Chinese Medicine in Managing Rheumatoid Arthritis: An Integrative Review of Clinical and Molecular Findings
作者
Jianting Wen, Jian Liu, Lei Wan, Fanfan Wang, Yang Li
主要结果：中药活性成分与复方可多靶点干预 RA 复杂发病机制（抑制促炎因子、诱导滑膜细胞凋亡、调控铁死亡与焦亡等新型细胞死亡通路、抗氧化、抗血管新生、改善高凝、恢复肠道菌群稳态）；ncRNA 在介导疗效中起关键作用；RCT、队列与真实世界数据一致证实中医药干预可缓解 RA 症状、改善关节功能并降低疾病活动度，疗效与安全性良好。
局限：叙述性综述，未进行定量 Meta 分析；纳入原始研究异质性较大；多数临床证据样本量有限、随访期短；具体分子靶点、最优方药配伍及长期临床结局仍需深入研究。
临床或科研意义：构建了从临床前到临床的完整证据链，以现代科学验证传统中医“痹证”理论；提示中医药是 RA 药物发现与中西医结合治疗策略的重要资源，为全球转化应用提供方向。
英文原摘要（English Abstract，源自 PubMed）：Traditional Chinese medicine (TCM) has a long-standing history in the treatment of rheumatoid arthritis (RA), known as "Bi Zheng," and offers a comprehensive therapeutic approach characterized by multi-target and multi-pathway mechanisms. Modern pharmacological research has demonstrated that bioactive compounds and herbal formulas derived from TCM (e.g., triptolide [TPL] from Tripterygium wilfordii and the Xinfeng Capsule [XFC]) effectively interfere with the complex pathogenesis of RA. These interventions modulate diverse pathological processes, including the suppression of pro-inflammatory cytokines (e.g., TNF-α, IL-6, and IL-1β), induction of apoptosis in hyperplastic synovial cells, and regulation of novel cell death pathways (such as ferroptosis and pyroptosis). Furthermore, TCM components exhibit potent antioxidant properties, inhibit pathological angiogenesis, ameliorate hypercoagulable states, and restore gut microbiota dysbiosis, which is increasingly recognized as a key environmental factor in RA development. Notably, emerging evidence highlights the critical role of non-coding RNAs (ncRNAs) as mediators of these therapeutic effects. Concurrently, a growing body of clinical evidence from randomized controlled trials (RCTs), cohort studies, and real-world data mining consistently confirms the significant efficacy and safety of TCM interventions in relieving RA symptoms, improving joint function, and reducing disease activity. By integrating preclinical and clinical findings, a robust evidence chain emerges, validating traditional TCM concepts through modern scientific rigor. Therefore, TCM represents a valuable resource for RA drug discovery and integrative treatment strategies. Further in-depth investigation is needed into its specific molecular targets, optimal formulations, and long-term clinical outcomes to facilitate its global translation and application.
中文摘要翻译：中医药在类风湿关节炎（RA）治疗中有着悠久历史，中医称之为“痹证”，其治疗以多靶点、多通路作用为特征。现代药理学研究表明，源自中医药的生物活性化合物与复方（如雷公藤的雷公藤甲素[TPL]与新风胶囊[XFC]）可有效干预RA 的复杂发病机制。这些干预调节多种病理过程，包括抑制促炎细胞因子（如 TNF-α、IL-6 与 IL-1β）、诱导增生活跃的滑膜细胞凋亡，以及调控新型细胞死亡通路（如铁死亡与焦亡）。此外，中药成分具有强抗氧化作用、抑制病理性血管新生、改善高凝状态，并恢复肠道菌群失调——后者日益被认为是 RA 发病的关键环境因素。值得注意的是，新兴证据强调非编码RNA（ncRNA）在这些疗效中作为介质的关键作用。与此同时，来自随机对照试验（RCT）、队列研究与真实世界数据挖掘的大量临床证据一致证实，中医药干预在缓解 RA 症状、改善关节功能与降低疾病活动度方面具有显著疗效与良好安全性。通过整合临床前与临床发现，形成了稳健的证据链，以现代科学严谨性验证了传统中医理论。因此，中医药是 RA 药物发现与整合治疗策略的宝贵资源。其具体分子靶点、最优方药配伍与长期临床结局仍需深入探究，以促进其全球转化与应用。
英文原摘要（English Abstract，源自 PubMed）：Pulmonary arterial hypertension (PAH) is characterized by pulmonary vascular remodeling and right heart dysfunction, driven largely by excessive proliferation of pulmonary arterial smooth muscle cells (PASMCs). The PI3K/AKT and MAPK signaling pathways are key regulators of this aberrant proliferation. This study investigated whether Ganoderma lucidum spore powder (GLSP), a traditional Chinese medicine with cardiovascular protective effects, ameliorates PAH through modulation of these pathways. In vivo, GLSP administration to monocrotaline (MCT)-induced PAH rats significantly reduced mean pulmonary arterial pressure and right ventricular systolic pressure, attenuated pulmonary vascular wall thickening and fibrosis, and improved right ventricular function, accompanied by suppression of PI3K/AKT and MAPK phosphorylation. In vitro, GLSP reversed PDGFBB-induced PASMC proliferation, migration, and activation of PI3K/AKT and MAPK signaling. Network pharmacology and molecular docking further revealed that GLSP components stably bind to AKT1, SRC, PIK3CA, HSP90AA1, and ESR1-key nodes within these pathways. Our findings, from both in vivo and in vitro experiments, demonstrate that GLSP ameliorates MCT-induced PAH and pulmonary vascular remodeling by inhibiting aberrant PASMC proliferation and migration via suppression of the PI3K/AKT and MAPK signaling axes, highlighting GLSP as a promising therapeutic candidate for PAH.
英文文献均标注【摘要/全文可得状态】：3 篇英文入选文献（PMID 42608732、42610193、42611346）目前均未见开放获取版本（OpenAlex 判定 closed，Unpaywall 因 DOI 过新暂无记录），仅保证题录与摘要可得，全文需通过机构订阅获取；如需全文，请通过 DOI 链接访问出版社页面。